← Back to patent-cliff list
Elexacaftor/ivacaftor/tezacaftor
Tier B — Position earlyElexacaftor/ivacaftor/tezacaftor
Vertex Pharmaceuticals Incorporated
Originator
2019
First approval
-
Expiry (public)
$10.31B ▲
Peak sales
Small molecule
Type
Targets：CFTR, PGY1
Brand：TRIKAFTA, Trikafta, Kaftrio
Indications (approved)：Cystic fibrosis
Regional status
US
Approved
2019-10-21
EU
Approved
2020-08-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Elexacaftor/ivacaftor/tezacaftor?
Approved indications include: Cystic fibrosis.
When does the Elexacaftor/ivacaftor/tezacaftor patent expire?
No public expiry year is available for Elexacaftor/ivacaftor/tezacaftor yet; this page updates once verified.
How do I get a quote for Elexacaftor/ivacaftor/tezacaftor intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29